Literature DB >> 19414761

Effector/memory but not naive regulatory T cells are responsible for the loss of concomitant tumor immunity.

Yung-Chang Lin1, Li-Yuan Chang, Ching-Tai Huang, Hui-Min Peng, Avijit Dutta, Tse-Ching Chen, Chau-Ting Yeh, Chun-Yen Lin.   

Abstract

The phenomenon of concomitant tumor immunity involves a tumor-bearing host rejecting another similar tumor at a distant site and suggests the existence of tumor-specific immunity. Loss of this immunity may contribute to tumor metastasis. However, mechanisms underlying the loss of concomitant immunity are largely unknown. We set up a concomitant tumor immunity model in which this immunity is gradually lost as the primary tumor progresses. We found that CD8(+) T cells, especially tumor-infiltrating CD8(+) T cells, from mice that lost concomitant tumor immunity, possessed potent antitumor properties and strongly expressed effector molecules. Furthermore, effector/memory regulatory T cells (Treg cells, CD103(+)CD4(+)Foxp3(+) T cells) increased as the primary tumor progressed. They initially accumulated around the tumor and in the spleen at later points. Not only did these cells more greatly express killing molecules, they also suppressed the functions of tumor-bearing CD8(+) T cells in vitro and in vivo. Finally, we show that these effector/memory Treg cells inhibit concomitant tumor immunity in vivo. Taken together, data suggest that effector/memory Treg cells are responsible for the loss of concomitant tumor immunity associated with tumor progression.

Entities:  

Mesh:

Year:  2009        PMID: 19414761     DOI: 10.4049/jimmunol.0803829

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  Cross-talk between tumors can affect responses to therapy.

Authors:  Christel Devaud; Liza B John; Jennifer A Westwood; Carmen Sm Yong; Paul A Beavis; Reto A Schwendener; Phillip K Darcy; Michael H Kershaw
Journal:  Oncoimmunology       Date:  2015-06-17       Impact factor: 8.110

Review 2.  Targeting regulatory T cells for improving cancer therapy: Challenges and prospects.

Authors:  Bilikere S Dwarakanath; Abdullah Farooque; Seema Gupta
Journal:  Cancer Rep (Hoboken)       Date:  2018-05-15

3.  Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy.

Authors:  Kazuhide Sato; Noriko Sato; Biying Xu; Yuko Nakamura; Tadanobu Nagaya; Peter L Choyke; Yoshinori Hasegawa; Hisataka Kobayashi
Journal:  Sci Transl Med       Date:  2016-08-17       Impact factor: 17.956

4.  Depletion of CD25⁺ T cells from hematopoietic stem cell grafts increases posttransplantation vaccine-induced immunity to neuroblastoma.

Authors:  Weiqing Jing; Xiaocai Yan; William H D Hallett; Jill A Gershan; Bryon D Johnson
Journal:  Blood       Date:  2011-04-26       Impact factor: 22.113

5.  The role of regulatory T cells in cancer.

Authors:  Tai-You Ha
Journal:  Immune Netw       Date:  2009-12-31       Impact factor: 6.303

6.  TAK1 regulates endothelial cell necroptosis and tumor metastasis.

Authors:  Lida Yang; Sayali Joseph; Tianliang Sun; Julia Hoffmann; Sophia Thevissen; Stefan Offermanns; Boris Strilic
Journal:  Cell Death Differ       Date:  2019-01-25       Impact factor: 15.828

7.  Blockade of TNF-α signaling benefits cancer therapy by suppressing effector regulatory T cell expansion.

Authors:  Li-Yuan Chang; Yung-Chang Lin; Jy-Ming Chiang; Jayashri Mahalingam; Shih-Huan Su; Ching-Tai Huang; Wei-Ting Chen; Chien-Hao Huang; Wen-Juei Jeng; Yi-Cheng Chen; Shi-Ming Lin; I-Shyan Sheen; Chun-Yen Lin
Journal:  Oncoimmunology       Date:  2015-04-16       Impact factor: 8.110

8.  Sustained Delivery of Carfilzomib by Tannic Acid-Based Nanocapsules Helps Develop Antitumor Immunity.

Authors:  Maie S Taha; Gregory M Cresswell; Joonyoung Park; Wooin Lee; Timothy L Ratliff; Yoon Yeo
Journal:  Nano Lett       Date:  2019-11-04       Impact factor: 11.189

9.  Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells.

Authors:  Vivian L Weiss; Timothy H Lee; Hong Song; Theodore S Kouo; Chelsea M Black; George Sgouros; Elizabeth M Jaffee; Todd D Armstrong
Journal:  PLoS One       Date:  2012-02-16       Impact factor: 3.240

Review 10.  The Liver-Immunity Nexus and Cancer Immunotherapy.

Authors:  James C Lee; Michael D Green; Laura A Huppert; Christine Chow; Robert H Pierce; Adil I Daud
Journal:  Clin Cancer Res       Date:  2021-07-20       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.